New data has revealed that millions of people in the UK are turning to GLP‑1 weight loss drugs, marking a rapid surge in ...
GLP-1’s drugs continue to expand horizons in gastroenterology, bariatrics, diabetes and chronic disease care — but the scale of the drugs’ adoption could be creating new areas of risk management for ...
A ₹1,000 crore market is set to grow 5x to ₹5,000 crore by 2030 as prices drop 40–50% post patent expiry. Three early movers ...
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ...
Medindia on MSN
Genetic link found: Why GLP-1 diabetes drugs may fail
India, April 17 -- Approximately 10% of the population carries specific genetic variants that cause GLP-1 (Glucagon-like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results